dr. Nicolas Kint (MD, PhD)

Multiple myeloma (MM) is the second most common hematological malignancy and is currently still considered an incurable disease, with most patients relapsing and eventually succumbing to the disease or its complications.  The division of clinical hematology at UZ Gent is actively involved in a large quantity of clinical trials in MM, ranging from phase 1 to phase 3 or postmarketing trials, as well as investigator-initiated trials. These trials specifically focus on the development of novel immune therapy modalities in MM, such as CAR-T cell therapy and bispecific antibody therapy.
Dr Kint is currently actively involved in all clinical trials at UZ Gent involving MM or AL amyloidosis, either as a primary investigator or subinvestigator.  
 

Dr Kint is a clinical hematologist at the University Hospital Ghent with a special interest in the treatment of plasma cell disorders, including multiple myeloma and AL amyloidosis. Following his medical training at the KU Leuven, he completed his specialty training in internal medicine and clinical hematology at the same university. He completed his doctoral training at the KU Leuven under the supervision of prof. Michel Delforge in 2019, entitled ‘In search of novel working mechanisms of proteasome inhibitors in multiple myeloma’. During his doctoral training, he was a visiting research scientist at the University of Navarra in Pamplona, Spain (prof. Bruno Paiva). For his research, he received the ‘ASH abstract achievement award’ from the American Society of Hematology in 2018. Following his hematology training, he performed a fellowship in clinical hematology at UZ Brussel.
Dr Kint is currently actively involved in all clinical trials at UZ Gent involving MM or AL amyloidosis, either as a primary investigator or subinvestigator. He is a member of the Belgian Hematology Society and the European Hematology Association, and is an active member in the myeloma subcommittee of the Belgian Hematology Society.
 

• Concise review: Multiple Myeloma in the Very Elderly: How do Novel Agents Fit in? Journal of Geriatric Oncology 2016 (PMID: 27567255)
• Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes, Nature Communications, 2018 (PMID: 29402884)
• The treatment of multiple myeloma in an era of precision medicine, Expert Review on Precision Medicine and Drug Development, 2019 
• Carfilzomib-induced reticulocytosis in patients with multiple myeloma is caused by impaired erythroid maturation, Leukemia 2020 (PMID: 31467428)
• Immunomodulators in newly diagnosed multiple myeloma: current and future concepts.  Expert Review in Hematology, 2021 (PMID: 33733978)
• Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients, Oncotargets and Therapy, 2022 (PMID: 35310960)
   

• Department Clinical Hematology (UZ Gent)
• LinkedIn 
• dr. Nicolas Kint is involved in Oncologisch Centrum UZ Gent
• dr. Nicolas Kint is interested to receive invitations for talks or presentations